 |
|
|
| |
Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6
Hepatitis C Virus Infection: An Integrated Analysis
|
| |
| |
Reported by Jules Levin
EASL 2017
52nd Annual Meeting of the European Association for the Study of the Liver, 19-23 April 2017, Amsterdam, the Netherlands
Jean-Francois Dufour1, Eli Zuckerman2, Neddie Zadeikis3, Christophe Hezode4, Seung Woon Paik5, Pietro Andreone6, Ola Weiland7,
Jihad Slim8, Steven L Flamm9, Timothy Morgan10, Hugo Vargas11, Simone Strasser12, Ashley Brown13, Yao Yu3, Ariel Porcalla3, Federico J Mensa3
1University Clinic for Visceral Surgery and Medicine, Inselspital, Bern, Switzerland; 2Carmel Medical Center Liver Insti tute, Haifa, Israel; 3AbbVie Inc., North Chicago, Illinois, United States; 4Hopital Henri Mondor, Universite Paris-Est, Creteil, France;
5Samsung Medical Center, Seoul, Republic of Korea; 6Dipartimento di Scienze Mediche e Chirurgiche, University of Bologna, Bologna, Italy; 7Karolinska University Hospital Huddinge, Karolinska Institutet, Stockholm, Sweden;
8St. Michael's Medical Center, Newark, New Jersey, United States; 9Northwestern Feinberg School of Medicine, Chicago, Illinois, United States; 10Veteran's Affairs Long Beach Healthcare System, Long Beach, California, United States;
11Mayo Clinic, Phoenix, Arizona, United States; 12Royal Prince Alfred Hospital, Sydney, New South Wales, Australia; 13Imperial College Healthcare, London, United Kingdom
|
| |
|
|
|
|
|
